KORU Medical Systems Reports 20.9% Revenue Growth in Q2 2025

KORU Medical Systems, Inc. reported a significant increase in financial performance for the second quarter of 2025, with net revenues reaching $10.2 million, a 20.9% rise from $8.4 million in the same period last year. The growth was primarily driven by a 15.3% increase in domestic core revenues, totaling $7.1 million, and a 33.9% increase in international core revenues, which amounted to $2.2 million. Additionally, the company saw a 42.1% increase in its pharma services and clinical trials segment, contributing $0.9 million to the total revenue. Gross profit for the quarter was $6.5 million, reflecting an 18.2% increase compared to $5.5 million in the prior year, although gross margin slightly decreased to 63.5% from 65.0% due to a one-time inventory valuation adjustment in the previous year.

In terms of operational metrics, KORU Medical's total operating expenses rose to $6.8 million from $6.7 million year-over-year, driven by increased selling, general, and administrative expenses, as well as research and development costs. The company reported a net loss of $0.2 million for the quarter, a significant improvement from a loss of $0.99 million in the same quarter of 2024, primarily due to increased gross profit. The weighted average number of common shares outstanding was 46.2 million, resulting in a basic and diluted net loss per share of $(0.00) for the quarter.

KORU Medical's balance sheet as of June 30, 2025, showed total assets of $25.5 million, down from $27.2 million at the end of 2024. Current assets decreased to $17.6 million, primarily due to a reduction in cash and cash equivalents, which stood at $8.1 million, down from $9.6 million. The company’s total liabilities also decreased to $9.0 million from $10.4 million, reflecting a reduction in accounts payable and accrued expenses. Stockholders' equity was reported at $16.5 million, slightly down from $16.8 million at the end of the previous fiscal year.

Looking ahead, KORU Medical anticipates continued growth driven by its core domestic and international markets, as well as its pharma services and clinical trials segment. The company plans to invest in research and development and manufacturing capabilities to support future growth and maintain product quality. However, management noted potential challenges, including inflation, tariffs, and market conditions, which could impact future performance. The company expects that its current cash position and operational cash flows will be sufficient to meet its needs for at least the next twelve months, although it may consider additional financing options to support its strategic initiatives.